Biogen Inc
NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024
BIIB Articles
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
With less than one-third of the year remaining, many portfolio managers are looking for some outperformance so they can catch up to whatever benchmark they are chasing.
Published:
Last Updated:
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
Published:
ThinkstockWith the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back into the coverage world and have reinitiated research analysis on some of...
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 29, 2014. They include AcelRx, Alcoa, Costco, Lululemon, Walmart and Trulia.
Published:
ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will change...
Published:
Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would like to see several competing biotechs join in on the fun.
Published:
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector, or in the case of...
Published:
A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally from the hard sell-off. Here are the top large cap biotech stocks to buy at...
Published:
Last Updated:
ThinkstockActivist investor Carl Icahn filed documents with the Security and Exchange Commission (SEC) late Friday announcing that he had acquired a 9.4% stake in Family Dollar Stores Inc. (NYSE:...
Published:
Last Updated:
A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as a "return to normalcy" following the roller coaster ride of early 2014.
Published:
ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty pharmaceutical companies making announcements and presenting clinical data. The...
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 29, 2014. They include AngloGold Ashanti, Twitter, Biogen Idec, Celgene, HomeAway and VMware.
Published: